arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Sunshine Biopharma Inc.

SBFM
$1.24 ▼ -0.16 (-11.43%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
66 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

Sunshine Biopharma Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $6.1M
Dividend Yield
Revenue Growth -9.1%
Op. Margin -17.3%
ROIC -6.5%
FCF / Share $-0.42
Trailing P/E
Price / Book 0.3x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

66-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$8.09M
↓ -9.1%
Net Income Profit after all expenses
$-1.24M
↓ -5.4%
Operating Margin Operating profit as % of sales
-17.3%
↑ +17.3% 11th
FCF / Share Free cash flow per share
$-0.42
↑ +33.5%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
11
Returns
25
Cash Quality
61

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 66 quarters